Market Closed -
Nasdaq
03:59:53 2024-05-15 pm EDT
|
5-day change
|
1st Jan Change
|
1.79
USD
|
-1.10%
|
|
+1.70%
|
+2.87%
|
Fiscal Period: September |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
35.06
|
35.24
|
7.174
|
5.015
|
5.556
|
-
|
-
|
Enterprise Value (EV)
1 |
35.06
|
35.24
|
7.174
|
5.015
|
5.556
|
5.556
|
5.556
|
P/E ratio
|
-
|
-0.59
x
|
-0.21
x
|
-0.16
x
|
-1.03
x
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
72.9
x
|
20.5
x
|
33.9
x
|
47.5
x
|
-
|
-
|
EV / Revenue
|
-
|
72.9
x
|
20.5
x
|
33.9
x
|
47.5
x
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-0.45
x
|
-
|
-
|
EV / FCF
|
-
|
-1.56
x
|
-
|
-
|
-0.44
x
|
-0.26
x
|
-0.2
x
|
FCF Yield
|
-
|
-64%
|
-
|
-
|
-229%
|
-380%
|
-506%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
44.3
|
189
|
222
|
1,750
|
3,070
|
-
|
-
|
Reference price
2 |
791.6
|
186.6
|
32.34
|
2.865
|
1.810
|
1.810
|
1.810
|
Announcement Date
|
12/17/20
|
12/17/21
|
12/15/22
|
12/14/23
|
-
|
-
|
-
|
Fiscal Period: September |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.4836
|
0.3499
|
0.1478
|
0.117
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-12.4
|
-
|
-
|
EBIT
1 |
-
|
-25.09
|
-
|
-18.79
|
-8.656
|
-21
|
-28
|
Operating Margin
|
-
|
-5,187.32%
|
-
|
-12,714.04%
|
-7,398.01%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-24.98
|
-
|
-18.83
|
-7.13
|
-
|
-
|
Net income
1 |
-
|
-24.98
|
-
|
-18.83
|
-7.13
|
-21
|
-28
|
Net margin
|
-
|
-5,165.92%
|
-
|
-12,741.15%
|
-6,094.02%
|
-
|
-
|
EPS
2 |
-
|
-314.2
|
-150.5
|
-18.14
|
-1.760
|
-
|
-
|
Free Cash Flow
1 |
-
|
-22.56
|
-
|
-
|
-12.7
|
-21.1
|
-28.1
|
FCF margin
|
-
|
-4,663.87%
|
-
|
-
|
-10,854.7%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/17/20
|
12/17/21
|
12/15/22
|
12/14/23
|
-
|
-
|
-
|
Fiscal Period: September |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.4836
|
0.1298
|
0.0953
|
0.0621
|
0.0628
|
0.0373
|
0.0364
|
0.0368
|
0.0373
|
0.0186
|
0.0123
|
0.019
|
0.0187
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-6.947
|
-6.215
|
-8.21
|
-7.867
|
-
|
-
|
-
|
-
|
-3.6
|
-1.279
|
-1.604
|
-1.78
|
-1.97
|
Operating Margin
|
-1,436.4%
|
-4,788.1%
|
-8,613.32%
|
-12,674.77%
|
-
|
-
|
-
|
-
|
-9,662.24%
|
-6,864.57%
|
-13,012.98%
|
-9,365.79%
|
-10,554.37%
|
Earnings before Tax (EBT)
1 |
-6.952
|
-6.201
|
-8.208
|
-7.877
|
-
|
-
|
-
|
-
|
-3.677
|
-1.169
|
0.553
|
-1.766
|
-1.963
|
Net income
1 |
-6.952
|
-6.201
|
-8.208
|
-7.877
|
-
|
-
|
-
|
-
|
-3.677
|
-1.169
|
0.553
|
-1.766
|
-1.963
|
Net margin
|
-1,437.48%
|
-4,777.33%
|
-8,611.52%
|
-12,690.54%
|
-
|
-
|
-
|
-
|
-9,867.79%
|
-6,272.2%
|
4,485%
|
-9,297.37%
|
-10,514.19%
|
EPS
2 |
-27.72
|
-30.80
|
-43.12
|
-40.04
|
-37.18
|
-17.60
|
-7.480
|
-2.860
|
-17.28
|
-0.3100
|
-0.2767
|
-0.6900
|
-0.4800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/17/21
|
2/8/22
|
5/10/22
|
8/15/22
|
12/15/22
|
2/13/23
|
5/10/23
|
8/14/23
|
12/14/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: September |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-22.6
|
-
|
-
|
-12.7
|
-21.1
|
-28.1
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
0.2
|
0.2
|
0.2
|
Capex / Sales
|
-
|
-
|
-
|
-
|
170.94%
|
-
|
-
|
Announcement Date
|
12/17/20
|
12/17/21
|
12/15/22
|
12/14/23
|
-
|
-
|
-
|
Last Close Price
1.81
USD Average target price
12.5
USD Spread / Average Target +590.61% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.02% | 5.56M | | +30.84% | 588B | | -3.42% | 364B | | +18.02% | 326B | | +4.27% | 285B | | +14.81% | 239B | | +9.77% | 210B | | -7.81% | 200B | | +8.12% | 167B | | -1.42% | 161B |
Other Pharmaceuticals
|